Rimonabant is an anorectic antiobesity biologic that has
been aloof from the bazaar due to potentially austere ancillary effects. It was
accustomed for use in Europe and added countries, but never accustomed in the
United States. Rimonabant is an changed agonist for the cannabinoid receptor
CB1. It has aswell been apparent to be a μ-opioid receptor adversary (possibly
the accidental agency in its appear dysphoric qualities). Its capital
aftereffect is abridgement in appetite.
It is broadly acclimated as a apparatus to investigate
CB receptor backdrop and the mechanisms by which CB agonists apply their
pharmacological effects. In rodent models and analytic trials, rimonabant finer
induces lipolysis, reduces hepatomegaly, decreases physique weight, and
improves dyslipidemia by abbreviation triglyceride, chargeless blubbery acid,
and absolute cholesterol levels and by accretion HDL/LDL ratios. However,
rimonabant reportedly produces adverse psychiatric and acoustic furnishings
(e.g., abasement or anxiety) and accordingly is not accustomed by the FDA for
use as a weight ascendancy medication.
more about:
No comments:
Post a Comment